Long-Term Proactive Management of Psoriasis Vulgaris with Fixed-Dose Combination of Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam: Results from a Phase III Randomized Controlled Trial

Mark Lebwohl,Charles Lynde,Diamant Thaçi,Jean-Philippe Lacour,Richard B Warren,Marie H Mørch,Monika Liljedahl

doi:10.25251/skin.4.supp.32

Abstract

Abstract not available.

Highlights

Topical therapies are considered first-line treatment for psoriasis,1 maintaining long-term disease control is a challenge, with many patients untreated or undertreated.2 Current topical psoriasis treatment relies on a reactive approach to disease flares, as opposed to a more long-term proactive approach.3Data supporting the efficacy and safety of calcipotriene 0.005% and betamethasone dipropionate 0.064% (Cal/BD) foam approved as a reactive treatment are available from trials of 4- and 12-weeks duration in patients with psoriasis vulgaris.4,5,6,7Here, we report the efficacy of Cal/BD foam in long-term proactive management of psoriasis over 52 weeks (NCT02899962)
We report the efficacy of Cal/BD foam in long-term proactive management of psoriasis over 52 weeks (NCT02899962)
To evaluate the efficacy of a twice-weekly proactive maintenance regimen with Cal/BD foam compared with reactive management with vehicle foam in the prevention of relapse in patients with psoriasis

Summary

Introduction

Topical therapies are considered first-line treatment for psoriasis, maintaining long-term disease control is a challenge, with many patients untreated or undertreated. Current topical psoriasis treatment relies on a reactive approach to disease flares, as opposed to a more long-term proactive approach.. Topical therapies are considered first-line treatment for psoriasis, maintaining long-term disease control is a challenge, with many patients untreated or undertreated.. Current topical psoriasis treatment relies on a reactive approach to disease flares, as opposed to a more long-term proactive approach.. Data supporting the efficacy and safety of calcipotriene 0.005% and betamethasone dipropionate 0.064% (Cal/BD) foam approved as a reactive treatment are available from trials of 4- and 12-weeks duration in patients with psoriasis vulgaris (plaque psoriasis).. We report the efficacy of Cal/BD foam in long-term proactive management of psoriasis over 52 weeks (NCT02899962). Data from the open-label lead-in phase of this trial are presented in poster #16830

Materials and Methods

Results

Conclusions